Inhibitors of signal transduction protein kinases as targets for cancer therapy

Biotechnology Annual Review

Volumn 12, Issue , 2006, Pages 153-223

  Mikalsen, Theresa ^a   Gerits, Nancy ^a   Moens, Ugo ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 7 HYDROXYSTAUROSPORINE; AP 23573; ARRY 142886; AZD 6244; BEVACIZUMAB; BRYOSTATIN 1; CANERTINIB; CEP 701; CETUXIMAB; DASATINIB; DOCETAXEL; ERLOTINIB; GEFITINIB; GELDANAMYCIN; GENE EXPRESSION MODULATOR 231; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LAPATINIB; LBH 589; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NB 1011; NILOTINIB; PANITUMUMAB; PD 18305; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; TEMSIROLIMUS; THYMECTACIN; THYMIDYLATE SYNTHASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CELL DIVISION; CLINICAL TRIAL; COLON CANCER; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MOUSE; MYELOID LEUKEMIA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; RAT; REVIEW; RNA INTERFERENCE; SEIZURE; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR CELL;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 33749436432     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(06)12006-2     Document Type: Review

References (256)

1. Cohen P. The origins of protein phosphorylation. Nat Cell Biol 4 (2002) E127-E130
2. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2005) 172-187
3. Tibes R., Trent J., and Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 45 (2005) 357-384
4. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
5. Bode A.M., and Dong Z. Signal transduction pathways in cancer development and as targets for cancer prevention. Prog Nucl Acid Res Mol Biol 79 (2005) 237-297
6. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., Mestan J., O'Reilly T., Traxler P., Chaudhuri B., Fretz H., Zimmermann J., Meyer T., Caravatti G., Furet P., and Manley P.W. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 93 (2002) 79-98
7. Dancey J., and Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2 (2003) 296-313
8. Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 7 (2003) 215-234
9. Sawyer T.K. Novel oncogenic protein kinase inhibitors for cancer therapy. Curr Med Chem Anti-Cancer Agents 4 (2004) 449-455
10. Force T., Kuida K., Namchuk M., Parang K., and Kyriakis J.M. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation 109 (2004) 1196-1205
11. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 36 (2003) 462-469
12. Ahn N.G., and Resing K.A. Cell biology. Lessons in rational drug design for protein kinases. Science 308 (2005) 1266-1267
13. Cohen M.S., Zhang C., Shokat K.M., and Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308 (2005) 1318-1321
14. Celmed Biosciences, 2005. http://www.celmedbio.com/english/products/NB1011.html
15. Groner B., Hartmann C., and Wels W. Therapeutic antibodies. Curr Mol Med 4 (2004) 539-547
16. Hinoda Y., Sasaki S., Ishida T., and Imai K. Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 95 (2004) 621-625
17. Friedrich I., Shir A., Klein S., and Levitzki A. RNA molecules as anti-cancer agents. Semin Cancer Biol 14 (2004) 223-230
18. Shir A., and Levitzki A. Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. Nat Biotechnol 20 (2002) 895-900
19. Sioud M. Therapeutic siRNAs. Trends Pharmacol Sci 25 (2004) 22-28
20. Taskén K., and Aandahl E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84 (2004) 137-167
21. Miller W.R. Regulatory subunits of PKA and breast cancer. Ann N Y Acad Sci 968 (2002) 37-48
22. Tortora G., and Ciardiello F. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. Ann N Y Acad Sci 1002 (2003) 236-243
23. Bossis I., and Stratakis C.A. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 145 (2004) 5452-5458
24. Chen H.X., Marshall J.L., Ness E., Martin R.R., Dvorchik B., Rizvi N., Marquis J., McKinlay M., Dahut W., and Hawkins M.J. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res 6 (2000) 1259-1266
25. Goel S., Desai K., Bulgaru A., Fields A., Goldberg G., Agrawal S., Martin R., Grindel M., and Mani S.A. A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin Cancer Res 9 (2003) 4069-4076
26. Goel S, Desai K, Macapinlac M, Wadler S, Goldberg G, Fields A, Einstein M, Volterra F, Wong B, Martin R and Mani S. A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1 alpha in patients with advanced solid cancers. Invest New Drugs 2005 (July 18) (Epub. ahead of print).
27. Miyata Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 11 (2005) 1131-1138
28. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., Sigua C., Sondarva G., Moscinski L., Atadja P., and Bhalla K. Combination of histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105 (2005) 1768-1776
29. Hanada M., Feng J., and Hemmings B.A. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta 1697 (2004) 3-16
30. Stephens P., Edkins S., Davies H., Greenman C., Cox C., Hunter C., Bignell G., Teague J., Smith R., Stevens C., O'Meara S., Parker A., Tarpey P., Avis T., Barthorpe A., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M., Leung S.Y., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B., Yuen S.T., Nicholson A.G., Lakhani S., Easton D.F., Weber B.L., Stratton M.R., Futreal P.A., and Wooster R. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37 (2005) 590-592
31. Leahy D.J. Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. Adv Protein Chem 68 (2004) 1-27
32. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995) 183-232
33. Menard S., Casalini P., Campiglio M., Pupa S.M., and Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 61 (2004) 2965-2978
34. Garcia-Echeverria C., and Fabbro D. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases. Mini Rev Med Chem 4 (2004) 273-283
35. Grandis J.R., and Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102 (2004) 37-46
36. http://www.iressa-us.com/news.asp
37. Dewji MR. Early phase I data on an irreversible pan-reb inhibitor: CI-1033. What did we learn? J Chemother 2004;16:44-48.
38. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Mihai D., Benedetti M.G., Carter T.A., Pietro Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lelias J.M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., and Lockhart D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature 23 (2005) 329-336
39. Calvo E., Tolcher A.W., Hammond L.A., Patnaik A., deBono J.S., Eiseman I.A., Olson S.C., Lenehan P.F., McCreery H., LoRusso P., and Rowinsky E.K. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schadule: a phase I pharmacokinetic and food effect study. Clin Cancer Res 10 (2004) 7112-7120
40. Nemunaitis J., Eiseman I., Cunningham C., Senzer N., Williams A., Lenehan P.F., Olson S.C., Bycott P., Schlicht M., Zentgraff R., Shin D.M., Ralph G., and Zinner R.G. Phase 1 clinical and pharmacokinetics evaluation of oral ci-1033 in patients with refractory cancer. Clin Cancer Res 11 (2005) 3846-3853
41. Crombet T., Osorio M., Cruz T., Roca C., del Castillo R., Mon R., Iznaga-Escobar N., Figueredo R., Koropatnick J., Renginfo E., Fernandez E., Torres D.O., Ramos M., Leonard I., Perez R., and Lage A. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22 (2004) 1646-1654
42. Spicer J. Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YMBioSciences/Oncoscience. Curr Opin Mol Ther 7 (2005) 182-191
43. Bode U. Presentation at the European High-grade Glioma Meeting, Rensburg, Germany, February 25, 2005.
44. Crombet T.R., Figueredo J., Catala M., Gonzalez S., Selva J.C., Toledo C., Torres O., Perez R., and Lage A. Treatment of high-grade astrocytic tumors with the humanized anti-EGFR antibody h-R3 and radiotherapy. J Clin Oncol 23 (2005) 2554
45. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., loyd M.B., Golas J., Hallett W.A., Johnson B.D., Nilakantan R., Overbeek E., Reich M.F., Shen R., Shi X., Tsou H.R., and Wissner A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64 (2004) 3958-3965
46. Tsou H.R., Overbeek-Klumpers E.G., Hallett W.A., Reich M.F., Floyd M.B., Johnson B.D., Michalak R.S., Nilakantan R., Discafani C., Golas J., Rabindran S.K., Shen R., Shi X., Wang Y.F., Upeslacis J., and Wissner A. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 48 (2005) 1107-1131
47. Anasetti C. High priority studies at Moffitt. Phase I and I/II. Clin Trials Update 6 (2005) 1-6
48. The Cleveland Clinic Taussig Cancer Center; http://www.clevelandclinic.org; 2005.
49. PhRMA; http://www.phrma.org/newmedicines; 2005.
50. Curnow R.T. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 45 (1997) 210-215
51. Sridhar S.S., Seymour L., and Shepherd F.A. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4 (2003) 397-406
52. Pfister D, Alla L, Robert B, Motzer R, Corinn W, Metz E, Sherman E and Curnow R. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors. 1999 ASCO Annual Meeting, Abstract 1667.
53. Clinicaltrials.gov. http://clinicaltrials.gov/, 2005.
54. http://www.healthsystem.Virginia.edu
55. Tyagi P. Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 5 (2005) 21-23
56. Shiqing L., Schmitz K.R., Jeffrey P.D., Wiltzius J.J.W., Kussie P., and Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7 (2005) 301-311
57. Hoff P.M. Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Semin Oncol 31 (2004) 17-21
58. Hoekstra R., Dumez H., van Oosterom A.T., Sizer K.C., Ravera C., Vaidyanathan S., Verweij J., and Eskens F.A. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer. Proc Am Soc Clin Oncol 21 (2002) 86a
59. Murren J.R., Papadimitrakopoulou V.A., Sizer K., Vaidyanathan S., Ravera C., and Abbruzzese J.L. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 21 (2002) 95a
60. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23 (2005) 3235-3242
61. Kim T. Technology evaluation: Matuzumab. Curr Opin Mol Therap 6 (2004) 1-8
62. Vanhoefer U., Tewes M., Rojo F., Dirsh O., Schleucher N., Rosen O., Tillner J., Kovar A., Braun A.H., Trarbach T., Seeber S., Harstrick A., and Baselga J. Phase I study of the humanized anti-epidermal grwoth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22 (2004) 175-184
63. Sieden M., Burris H.A., Matulonis U., Hall J., Armstrong D., Speyer J., Tillner J., Weber D., and Muggia F. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced muellerian malignancies. J Clin Oncol 23 (2005) 3151
64. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eierman W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
65. Stern M., and Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54 (2005) 11-29
66. Robert N.J. A patient with Her2-overexpressing metastatic breast cancer treated with paclitaxel/carboplatin plus trastuzumab. Case Studies Breast Cancer 3 (2004) 1-8
67. Gomez H.L., Chavez M.A., Dova D.C.l., Chow L.W.C., Wood B.A., Berger M.S., and Sledge G.W. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol 23 (2005) 3046
68. Agus B.D., Gordon M.S., Taylor C., Natale R.B., Karian B., Mendelson D.S., Press M.F., Allison D.E., Sliwkowski M.X., Lieberman G., Kelsey S.M., and Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23 (2005) 2534-2543
69. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., and Sliwkoski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 (2004) 317-328
70. Genentech. Omnitarg (Pertuzumab). http://www.biooncology.com/bioonc/ic_o.jsp, 2005.
71. Hidalgo M, Erlichman C, Rowinsky EK, Koepp-Norris J, Jensen K, Boni J, Korth-Bradley J, Quinn S and Zacharchuk C. Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), patients with advanced solid tumors, ASCO Annual Meeting, 2002, Abstract 65.
72. Bonomi P. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer 41 (2003) S43-S48
73. Tejpar S., and Casado E. Toxicity profile of the epidermal growth factor receptor inhibitor EKB-569 combined with fluoroacil-based chemotherapy in patients with advanced colorectal cancer. Cancer Abstr Summaries 5 (2004)
74. Cross M.J., Dixellus J., Matsumoto T., and Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 28 (2003) 488-494
75. Bergsland E.K. Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm 61 (2004) S4-S11
76. Bicknell R., and Harris A.L. Novel angiogenic signalling pathways and vascular targets. Annu Rev Pharmacol Toxicol 44 (2004) 219-238
77. Tammella T., Enholm B., Alitalo K., and Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 65 (2005) 550-563
78. Marx J. Encouraging results for second-generation antiangiogenesis drugs. Science 308 (2005) 1248-1249
79. Bioseeker. Analytical tool: Avastin and the competitive landscape. http://www.piribo.com/publications/diseases_conditions/cancer/BSK087.html, 2004.
80. Rugo H.S. Bevacizumab in the treatment of breast cancer: rationale and current data. The Oncologist 9 (2004) 43-49
81. Midgley R., and Kerr K. Bevacizumab - current status and future directions. Gan Bunshi-Hyoteki Chiryo 3 (2005) 124-132
82. Posey J.A., Ng T.C., Yang B., Khazaeli M.B., Carpenter M.D., Fox F., Needle M., aksal H., and LoBuglio A.F. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9 (2003) 1323-1332
83. Beebe J.S., Jani J.P., Knauth E., Goodwin P., Higdon C., Rossi A.M., Emerson E., Finkelstein M., Floyd E., Harriman S., Atherton J., Hillerman S., Soderstrom C., Kou K., Gant T., Noe M.C., Foster B., Rastinejad F., Marx M.A., Schaeffer T., Whalen P.M., and Roberts W.G. Pharmacological characterization of CP-547, 632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 63 (2003) 7301-7309
84. Cohen R.B., Simon G., Langer C.J., Schol J.R., McHale J., Eisenberg P., Hainsworth J.D., Liau K.F., and Healey D. Phase I trial of CP-547, 632 (VEGFR-2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22 (2004) 3014
85. Tolcher A, O'Leary JJ, DeBono J, Molpus K, Woodard C, Warnat M, Liau K, Noe D, Healy D and Huberman M. A phase I study of an oral vascular endothelial growth factor receptor2 (VEGFR2) tyrosine kinase inhibitor, CP547, 632, in patients with advanced solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, September 28-30, 2004.
86. S. Polawski, 2005. http://www.g-o-c.org/patient/Advocacy/trials/Hamilton/PFILZER.asp
87. OSI Annual report 2004. http://www.media.corporate-ir.net/mediafiles/NSD/OSIP/reports/OSIAR04.pfd
88. Gridelli C., Massarelli E., Maione P., Rossi A., Herbst R.S., Onn A., and Ciardiello F. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Cancer 101 (2004) 1733-1744
89. Heymach J.V. ZD6474 - clinical experience to date. Br J Cancer 92 (2005) S14-S20
90. Miller K.D., Trigo J.M., Wheeler C., Barge A., Rowbottom J., Sledge G., and Baselga J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11 (2005) 3369-3376
91. Cobleigh M.A., Langmuir V.K., Sledge G.W., Miller K.D., Haney L., Novotny W.F., Reimann J.D., and Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30 (2003) 117-124
92. Johnsen B.E., Ma P., West H., Kerr R., Prager D., Sandler A., Herbst R.S., Stewart D.J., Dimery I.W., and Heymach J.V. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. J Clin Oncol 23 (2005) 7102
93. Kovacs MJ, Reece DE, Marcellus D, Meyer R, Matthews S, Dong RP and Eisenhauer EA. A phase II study of ZD6474, a vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with relapsed multiple myeloma (MM). Blood 2004;104(11 Suppl):Abstract 346.
94. Drevs J., Medinger M., Mross K., Zirrgiebel U., Strecker R., Unger C., Puchalski T.A., Fernandes N., Roberston J., and Siegert P. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 23 (2005) 3002
95. Hwang JH. Inhibition of vascular endothelial growth factor receptor tyrosine kinase activity by small molecules. http://www.cancerpublications.com/newsletter/angiogenesis/VEGF/v1n2/articles3.html, 2004a.
96. Hwang J.H. Vasc Endothel Growth Factor Oncol 1 (2004) 11-14
97. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., Hu-Lowe D.D., Shalinsky D.R., Thurston G., Yancopoulos G.D., and McDonald D.M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165 (2004) 35-52
98. Gingrich D.E., Reddy D.R., Iqbal M.A., Singh J., Aimone L.D., Angeles T.S., Albom M., Yang S., Ator M.A., Meyer S.L., Robinson C., Ruggeri B.A., Dionne C.A., Vaught J.L., Mallamo J.P., and Hudkins R.L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hdyroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and uts dimethylglycerine ester prodrug clinical candidate CEP-7055. J Med Chem 46 (2003) 5375-5388
99. Pili R, Carducci MA, Brown P, Russel L and Hurwitz H. A phase I study of the pan-VEGFR tyrosine kinase inhibitor, CEP-7055, in patients with advanced malignancy. Proc Am Soc Clin Oncol 2003;22:207, Abstract 831.
100. Ruggeri R., Singh J., Gingrich D., Angeles T., Albom M., Chang H., Robinson C., Hunter K., Dobrzanski P., Jones-Bolin S., Aimone L., Klein-Szanto A., Herbert J.M., Bono F., Schaeffer P., Casellas P., Bourie B., Pili R., Isaacs J., Ator M., Hudkins R., Vaught J., Mallamo J., and Dionne C. CEP-7055: a novel, orally pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 63 (2003) 5978-5991
101. Dumas J., Smith R.A., and Lowinger T.B. Recent development in the discovery of protein kinase inhibitors from the urea class. Curr Opin Drug Discov Dev 7 (2004) 600-616
102. Zangari M., Anaissie E., Stopeck A., Morimoto A., Tan N., Lancet J., Cooper M., Hanah A., Garcia-Manero G., Faderl S., Kantarjian H., Cherrinton J., Albitar M., and Giles F.J. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10 (2004) 88-95
103. Arora A., and Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315 (2005) 971-979
104. Britten CD, Rosen LS, Kabbinavar F, Rosen P, Mulay M, Hernandez L, Brown J, Bello C, Kelsey SM and Scigalla P. Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. American Society of Clinical Oncology Annual Meeting 2002, Abstract 1922.
105. Shepherd F.A., and Sridhar S.S. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 41 (2003) 563-572
106. Davis D.W., Takamori R., Raut C.P., Xiong H.Q., Herbst R.S., Stadler W.M., Heymach J.V., Demetri G.D., Rashid A., Shen Y., Wen S., Abbruzzese J.L., and McConkey D.J. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 and SU6668. Clin Cancer Res 11 (2005) 678-689
107. Abrams T.J., Murray L.J., Presenti E., Holway V.W., Colombo T., Lee L.B., Cherrington J.M., and Pryer N.K. Preclinical evaluation of the tyrosine kinase inhibitor su11248 as a single agent and in combination with "standard of care" therapeutic agents for the therapy of breast cancer. Mol Cancer Ther 2 (2003) 1011-1021
108. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar O.J., Sukbuntherng J., Blake R.A., Tang L.S.A.C., Miller T., Shirazian S., McMahon G., and Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
109. Yee K.W.H., Schittenheim M., O'Farrel A.M., Town A.R., McGreevey L., Bainbridge T., Cherrington J.M., and Heinrich M.C. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 104 (2004) 4202-4209
110. Fiedler W., Serve H., Dohner H., Schwittay M., Ottmann O.G., O'Farrell A.M., Bel lo C.L., Allred R., Manning W.C., Cherrington J.M., Louie S.G., Hong W., Brega N.M., Massimini G., Scigalla P., Berdel W.E., and Hossfeld D.K. A phase I study of SU11248 in the treatment of patients with refractory or resistent acute myeloid leukemia (AML) or not amenable to conventional therapy for disease. Blood 105 (2005) 986-993
111. http://www.multi-targetedtherapy.com
112. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfiled M.A., Mross K., Ball H.A., Lucy Lee L., Mietlowski W., Fuxius S., Unger C., O'Byrne K., Henry A., Cherryman G.R., Laurent D., Dugan M., Marme D., and Steward W.P. Dynamic contrast-enhanced magnetic resonance imaging as a biomartker for the pharmacological response of PTK787/ZK222584, an inhibito of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastasis: results from two phase I studies. J Clin Oncol 21 (2003) 3955-3964
113. Qian D.Z., Wang X., Kachhap S.K., Kato Y., Wei Y., Zhang L., Atadja P., and Pili R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64 (2004) 6626-6634
114. Drevs J., Zirrgiebel U., Schmidt-Gersbach C.I.M., Mross K., Medinger M., Lee L., Pinheiro J., Wood J., Thomas A.L., Unger C., Henry A., Steward W.P., Laurent D., Lebwohl D., Dugan M., and Marme D. Soluble markers for the assessment of biological activity with PTK787/ZK222584 (PTK/ZK, a vascular endothelial growth factor receptor (VEGR)) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16 (2005) 558-565
115. Hess-Stumpp H., Haberey M., and Thierauch K.H. PTK787/ZK222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chem Biochem 6 (2005) 550-557
116. Venook A., Hurwitz H., Cunningham C., Burris H.A., Aitchison R., Radka S., Pavco P., Capra W., Wolin M., and Usman N. Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: results of a phase II trial of a ribozyme targeting the pre-mRNA of VEGFR-1 (angiozyme), in combination with chemotherapy. Proc Am Soc Clin Oncol 22 (2003) 256
117. Kobayashi H., Eckhardt S.G., Lockridge J.A., Rothenberg M.L., Sandler A.B., O'Bryant C.L., Cooper W., Holden S.N., Aitchison R.D., Usman N., Woil M., and Basche M.L. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 56 (2005) 329-336
118. Weng D.E., Masci P.A., Radka S.F., Jackson T.E., Weiss P.A., Ganapathi R., Elson P.J., Capra W.B., Parker V.P., Lockridge J.A., Cowens J.W., Usman N., and Borde E.C. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol Cancer Ther 4 (2005) 948-955
119. Jones A.V., and Cross N.C.P. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 61 (2004) 2912-2923
120. Strock C.J., Park J.I., Rosen M., Dionne C., Ruggeri B., Jone-Bolin S., Denmeade S.R., Ball D.W., and Nelkin B.D. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63 (2003) 5559-5563
121. Undevia S.D., Vogelzang N.J., Mauer A.M., Janisch L., Mani S., and Ratain M.J. Phase I clinical trial of CEP-2563 dichloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs 22 (2004) 449-458
122. Corbin A.S., Grisold I.J., LaRosee P., Yee K.W.H., Heinrich M.C., Reimer C.L., Druker B.J., and Deininger M.W.N. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104 (2004) 3754-3757
123. Herbst R, Kurzrock R, Parson M, Benjamin R, Chen L, Ng C, Ingram M, Wong S, Chang D and Rosen L. AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors. Poster is found at http://www.gistsupport.org/amg%20706.html.
124. Kitamura Y., and Hirota S. KIT as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61 (2004) 2924-2931
125. Gotlib J., Berubé C., Growney J.D., Chen C.C., George T.I., Williams C., Kajiguchi T., Ruan J., Lilleberg S.L., Durocher J.A., Lichy J.H., Wang Y., Cohen P.S., Arber D., Heinrich M.C., Neckers L., Galli S.J., Gilliland D.G., and Coutré S.E. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106 (2005) 2867-2870
126. Laird A.D., and Cherrington J.M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Invest Drugs 12 (2003) 51-64
127. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3 (2003) 650-665
128. Markovic A., MacKenzie K.L., and Lock R.B. FLT-3: a new focus in the understanding of acute leukemia. Int J Biochem Cell Biol 37 (2005) 1168-1172
129. Miknyoczki S.J., Chang H., Klein-Szanto A., Gionne C.A., and Ruggeri B.A. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 5 (1999) 2205-2212
130. Smith B.D., Levis M., Beran M., Gilles F., Kantarjian H., Berg K., Murphy K.M., Dauses T., Allebach J., and Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biological and clinical acitivity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3878
131. Marshall J.L., Kindler H., Deeken J., Bhargava P., Vogelzang N.J., Rizvi N., Luhtala T., Boylan S., Dordal M., Robertson P., Hawkins M.J., and Ratain M.J. Phase I trial of orally administered cep-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 23 (2005) 31-37
132. Eder J.P., Garcia-Carbonero R., Clark J.W., Supko J.G., Puchalski T.A., Ryan D.P., Deluca P., Wozniak A., Campbell A., Rothermel J., and LoRusso P. A phase I trial of daily oral 4′-N-benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs 22 (2004) 139-150
133. Monnerat C., Henriksson R., Le Cevalier T., Novello S., Berthaud P., Faivre S., and Raymond E. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 15 (2004) 316-323
134. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., Grandin W., Lebwohl D., Wang Y., Cohen P., Fox E.A., Neuberg D., Clark J., Gilliland D.G., and Griffin J.D. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60
135. Kelly L.M., Yu J.C., Boulton C.L., Apatira M., Li J., Sullivan C.M., Williams I., Amaral S.M., Curley D.P., Duclos N., Neuberg D., Scarborough R.M., Pandey A., Hollenbach S., Abe K., Lokker N.A., Gilliland D.G., and Giese N.A. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia. Cancer Cell 1 (2002) 421-432
136. http://www.dana-faber.org
137. Lamant L., Pulford K., Bischof D., Morris S.W., Mason D.Y., Delsol G., and Mariame B. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 156 (2000) 1711-1721
138. Pulford K., Lamant L., Espinos E., Jiang Q., Xue L., Turturro F., Delsol G., and Morris S.W. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci 61 (2004) 2939-2953
139. Pulford K., Morris S.W., and Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199 (2004) 330-358
140. A Phase II multi-dose study of SGN-30 (anti-CD30 mAb) in patients with refractory or recurrent Hodgkin's disease or anaplastic large cell ymphoma. http://data.umms.org/scripts/trial.cfm?ID=GCC%200425.
141. Sausville E.A., Arbuck S.G., Messmann R., Headlee D., Bauer K.S., Lush R.M., Murgo A., Figg W.D., Lahusen T., Jaken S., Jing X., Roberge M., Fuse E., Kuwabara T., and Senderowicz A.M. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19 (2001) 2319-2333
142. Turturro F., Arnold M.D., Frist A.Y., and Pulford K. Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin Cancer Res 8 (2002) 240-245
143. Johannessen M., Delghandi M.P., and Moens U. What turns CREB on? 16 (2004) 1211-1227
144. Saglio G., and Cillioni D. Abl: the prototype of oncogenic fusion proteins. Cell Mol Life Sci 61 (2004) 2897-2911
145. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5 (2005) 172-183
146. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
147. Duffaud F., and Blay J.Y. Gastrointestinal stromal tumors: biology and treatment. Oncology 65 (2003) 187-197
148. O'Hare T., Walters D.K., Deininger M.W.N., and Druker B.J. AMN107: tightening the grip of imatinib. Cancer Cell 7 (2005) 117-119
149. Doggrell S.A. BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin Invest Drugs 14 (2005) 89-91
150. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, Reddy MV and Reddy EP. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005;102:1992-1997. (Erratum in Proc Natl Acad Sci USA 2005;102:5635.)
151. http://www.irelandcancercenter.org
152. http://www.pharma.org
153. Playford M.P., and Schaller M.D. The interplay between Src and integrins in normal and tumor biology. Oncogene 23 (2004) 7928-7946
154. Johnston S.R.D. Clinical trials of intracellular signal transductions inhibitors for breast cancer - a strategy to overcome endocrine resistance. Endocr Relat Cancer 12 (2005) S145-S157
155. Poisson BA, Takimoto CH, Shapiro A, Gallot L, Nabhan C, Lieberman R and Bergan R. Pharmacokinetic analysis of the putative protstrate cancer chemopreventive agent, genistein. ASCO Meeting, 2001, Aabstract 334.
156. Takimoto C.H., Glover K., Huang X., Hayes S.A., Gallot L., Quinn M., Jovanovic B.D., Shapiro A., Hernandez L., Goetz A., Llorens V., Lieberman R., Crowell J.A., Poisson B.A., and Bergan R.C. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 12 (2003) 1213-1221
157. Karmanos Cancer Institute; http://www.karamanos.org.
158. Morris S.M., Chen J.J., Domon O.E., McGarrity L.J., Bishop M.E., Manjanatha M.G., and Casciano D.A. p53, mutations, and apoptosis in geni stein-exposed human lymphoblastoid cells. Mutat Res 405 (1998) 41-56
159. Abe T. Infantile leukemia and soybeans - a hypothesis. Leukemia 13 (1999) 317-320
160. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
161. Bellacosa A., Kumar C.C., Cristofano A.D., and Testa J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94 (2005) 29-86
162. Song G., Ouyang G., and Bao S. The activation of Akt/PKB signaling pathways and cell survival. J Cell Mol Med 9 (2005) 59-71
163. Senderowicz A.M. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2 (2003) S084-S095
164. Van Ummersen L., Binger K., Volkman J., Marnocha R., Tutsch K., Kolesar J., Arzoomanian R., Alberti D., and Wilding G. A phase I trials of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10 (2004) 7450-7456
165. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91 (2004) 1420-1424
166. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol Med 11 (2005) 353-361
167. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16 (2005) 525-537
168. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
169. Mita M.M., Rowinsky E.K., Goldston M.L., Mita A.C., Chu Q., Syed S., Knowles H.L., Rivera V.M., and Tolcher A.W. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor, administered iv daily x5 every other week in patients (pts) with refractory or advanced malignancies. J Clin Oncol 14S (2004) 3076
170. Desai A.A., Janisch L., Berk L.R., Knowles H.L., Rivera V.M., Bedrosian C.L., and Ratain M.J. A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis. J Clin Oncol 14S (2004) 3150
171. Feldman E, Giles F, Roboz G, Yee K, Curcio T, Rivera VM, Albitar M, Laliberte R and Bedrosian CL. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. ASCO Annual Meeting 2005, Abstract 6631.
172. Chawla SP, Sankhala KK, Chua V, Meendez LR, Eilber FC, Eckhardt JJ, Daly ST, Rana GS, Bedrosian CL and Demetri GD. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. ASCO Annual Meeting 2005, Abstract 9068.
173. http://www.ariad.com
174. Galanis E., Buckner J.C., Maurer M.J., Kreisberg J.I., Ballman K., Boni J., Peralba J.M., Jenkins R.B., Dakhill S.R., Morton R.F., Jaeckle K.A., Scheithauer B.W., Dancey J., Hidalgo M., and Walsh D.J. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: North Central Cancer Treatment Group. J Clin Oncol 23 (2005) 5294-5304
175. Galanis E., Buckner J.C., Maurer M.J., Hidalgo M., Kreisberg J.I., Peralba J.M., Jenkins R.B., and Walsh D.J. N997B: phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): updated results and correlative laboratory analysis. J Clin Oncol 23 (2005) 1505
176. Witzig T.E., Geyer S.M., Ghobrial I., Inwards D.J., Fonseca R., Kurtin P., Ansell S.M., Luyun R., Flynn P.J., Morton R.F.S., Dakhil R., Gross H., and Kaufmann S.H. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23 (2005) 5347-5356
177. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., Park Y., Liou S.H., Marshall B., Boni J.P., Dukart G., and Sherman M.L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
178. Prescott L.M. Meeting highlights: the 40th annual meeting of the American society of clinical oncology. Pharm Ther 29 (2004) 496-499
179. O'Donnell A., Faivre S., Judson I., Delbado C., Brock C., Lane H., Shand N., Hazell K., Armand J.P., and Raymond E. A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetics (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc Am Soc Clin Oncol 22 (2003) 200
180. van Oosterom A., Reichardt P., Blay J., Dumez H., Fletcher J., Debiec-Rychter M., Shand N., Drimitrijevic S., Yap A., and Demetri G. A phase I/II trial of the oral mTOR-inhibitor Everolimus (E) and Imatinib Mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: study update. J Clin Oncol 23 (2005) 9033
181. Pacey S., Rea D., Steven N., Brock C., Knowlton N., Shand N., Hazell K., Zoellner U., O'Donnell A., and Judson I. Results of a phase I clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and gemcitabine (GEM) in patients (pts) with advanced cancer. J Clin Oncol 22 (2004) 3120
182. Awada A, Cardoso F, Fontaine C, Dirix L, De Gréve J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Ressayre-Djaffer C and Piccart M. A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (Femarad ®), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole. 28th Annual San Antonio Breast Cancer Symposium, 2005.
183. Duke Comprehensive Cancer Center; http://www.cancer.duke.edu.
184. Milton D.T., Kris M.G., Azzoli C.G., Gomez J.E., Heelan R., Krug L.M., Pao W., Pizzo B., Rizvi N.A., and Miller V.A. Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 23 (2005) 7104
185. MD Anderson Cancer Center. 2005. http://www.utm-ext01a.mdacc.tmc.edu
186. Broaddus R.R., and Lu K.H. Future challenges in clinical and translational research for endometrial cancer. Int J Gynecol Cancer 15 (2005) 398-411
187. St. Jude Children's Research Hospital; http://www.stjude.org.
188. Roux P.P., and Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68 (2004) 320-344
189. Morin C.I., and Huot J. Recent advances in stress signaling in cancer. Cancer Res 64 (2004) 1893-1898
190. Viala E., and Pouyssegur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann N Y Acad Sci 1030 (2004) 208-218
191. Wellbrock C., Karasarides M., and Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5 (2004) 875-885
192. Baccarini M. Second nature: biological functions of the Raf-1 "kinase". FEBS Lett 579 (2005) 3271-3277
193. Storm S.M., and Rapp U.R. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 67 (1993) 201-210
194. Fransén K., Klintenäs M., Osterstrom A., Dimberg J., Monstein H.J., and Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25 (2004) 527-533
195. Lee J.W., Soung Y.H., Kim S.Y., Park W.S., Nam S.W., Min W.S., Kim S.H., Lee J.Y., Yoo N.J., and Lee S.H. Mutational analysis of the ARAF gene in human cancers. APMIS 113 (2005) 54-57
196. Strumberg D., and Seeber S. Raf kinase inhibitors in oncology. Onkologie 28 (2005) 101-107
197. Coudert B., Anthoney A., Fiedler W., Droz J.P., Dieras V., Borner M., Smyth J.F., Morant R., de Vires M.J., Roelvink M., and Fumoleau P. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur J Cancer 37 (2001) 2194-2198
198. Cripps M.C., Figueredo A.T., Oza A.M., Taylor M.J., Fields A.L., Holmlund J.T., McIntosh L.W., Geary R.S., and Eisenhauer E.A. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 8 (2002) 2188-2192
199. Tolcher A.W., Reyno L., Venner P.M., Ernst S.D., Moore M., Geary R.S., Chi K., Hall S., Walsh W., Dorr A., and Eisenhauer E. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8 (2002) 2530-2535
200. Oza A.M., Elit L., Swenerton K., Faught W., Ghatage P., Carey M., McIntosh L., Dorr A., Holmlund J.T., and Eisenhauer E. NCIC clinical trials group study (NCIC IND.116). Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol Oncol 89 (2003) 129-133
201. Rudin C.M., Marshall J.L., Huang C.H., Kindler H.L., Zhang C., Kumar D., Gokhale P.C., Steinberg J., Wanaski S., Kasid U.N., and Ratain M.J. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10 (2004) 7244-7251
202. Steinberg J.L., Mendelson D.S., Block H., Green S.B., Shu V.S., Parker K., Cullinan P., Dul J.L., von Hoff D.D., and Gordon M.S. Phase I study of LErafAON-ETU, an easy-to-use formulation of liposome entrapped c-raf antisense oligonucleotide, in advanced cancer patients. J Clin Oncol 23 (2005) 3214
203. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10 (2004) 6388s-6392s
204. Awada A., Hendlisz A., Gil T., Bartholomeus S., Mano M., de Valeriola D., Strumberg D., Brendel E., Haase C.G., Schwartz B., and Piccart M. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92 (2005) 1855-1861
205. Clark J.W., Eder J.P., Ryan D., Lathia C., and Lenz H.J. Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11 (2005) 5472-5480
206. Chudnovsky Y., Adams A.E., Robbins P.B., Lin Q., and Khavari P.A. Melanoma genetics and the development of rational therapeutics. J Clin Invest 1 15 (2005) 813-824
207. Minami H., Kawada K., Ebi H., Kitagawa K., Kim Y.I., Araki K., Mukai H., Tahara M., Nakajima H., and Nakajima K. A phase I study of BAY 43-9006, a dual inhibitor of Raf and VEGFR kinases, in Japanese patients with solid cancers. J Clin Oncol 23 (2005) 3062
208. Siu L.L., Winquist E., Agulnik M., Chin S.F., Pond G.R., Cheiken R., Francis P., Petrenciuc O., and Chen E.X. A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). J Clin Oncol 23 (2005) 5566
209. Adjei A.A., Mandrekar S., Marks R.S., Hanson L.J., Aranguren D., Jett J.R., Simantov R., Schwartz B., and Croghan G.A. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). J Clin Oncol 23 (2005) 3067
210. Eisen T., Ahmad T., Gore M.E., Marais R., Gibbens I., James M.G., Schwartz B., and Bergamini L. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J Clin Oncol 23 (2005) 7508
211. Steinbild S., Baas F., Gmehling D., Brendel E., Christensen O., Schwartz B., and Mross K. Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. J Clin Oncol 23 (2005) 3115
212. Flaherty K.T., Brose M., Schuchter L., Tuveson D., Lee R., Schwartz B., Lathia B., Weber B., and O'Dwyer P. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 22 (2004) 7507
213. Pharmacy Choice; http://www.pharmacychoice.com.
214. Pharmaceutical news; http://www.usc.edu.
215. Posadas E.M., Gulley J., Arlen P.M., Harold N., Fioravanti S., Meltzer P., Scripture C.D., Figg W.D., Kohn E.C., and Dahut W.L. A phase II study of BAY 43-9006 in patients with androgen-independent prostate cancer (AIPC) with proteomic profiling. J Clin Oncol 23 (2005) 4762
216. Virginia Piper Cancer Institute; http://www.allina.com.
217. Ratain M.J., Eisen T., Stadle W.M., Flaherty K.T., Gore M., Desai A., Patnaik A., Xiong H.Q., Schwartz B., and O'Dwyer P. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23 (2005) 4544
218. Toledo Community Hospital. http://www.tchop.com.
219. Onyx Pharmaceuticals; http://www.onyx-pharm.com.
220. Escudier B., Szczylik C., Eisen T., Stadler W.M., Schwartz B., Shan M., and Bukowski R.M. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 232005 (2005) LBA4510
221. Bansal A., Ramirez R.D., and Minna J.D. Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines. Oncogene 14 (1997) 1231-1234
222. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Baotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H and Hasemann CA. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11:1192-1197. (Erratum in Nat Struct Mol Biol 2005;12:278.)
223. Fang J.Y., and Richardson B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6 (2005) 322-327
224. Bioexchange. Array Biopharma achieves milestone for initiation of phase I clinical trial for anticancer compound ARRY-4886.http://www.bioexchange.com/news/new_page.cfm?id=20501.
225. Nezhat F., Wadler S., Muggia F., Mandeli J., Goldberg G., Rahaman J., Runowicz C., Murgo A.J., and Gardner G.J. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York gynecologic oncology group study. Gyn Oncol 93 (2004) 144-148
226. Thompson N., and Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5 (2005) 350-356
227. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., Hamid O., Varterasian M., Asbury P., Kaldjian E.P., Gulyas S., Mitchell D.Y., Herrera R., Sebolt-leopold J.S., and Meyer M.B. Multicenter phase II study of oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic patients. J Clin Oncol 22 (2004) 4442-4445
228. Allen L.F., Sebolt-Leopold J., and Meyer M.B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPK). Sem Oncol 30 (2003) 105-116
229. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4 (2004) 937-947
230. Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 4 (2004) 125-146
231. Koivunen J., Aaltonen V., and Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett 235 (2005) 1-10
232. Propper D.J., McDonald A.C., Thavasau A.M., Balkwill F., Braybrooke J.P., Caponigro F., Graf P., Dutreix C., Blackie R., Kaye S.B., Ganesan T.S., Talbot D.C., Harris A.L., and Twelves C. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19 (2001) 1485-1492
233. Virchis A., Ganeshaguru K., Hart S., Jones D., Fletcher L., Wright F., Wickremasinghe R., Man A., Csermak K., Meyer T., Fabbro D., Champain K., Yap A., Prentice H.G., and Mehta A. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol J 3 (2002) 131-136
234. Kortmansky J., and Schwartz G.K. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest 21 (2003) 924-936
235. Marshall J.L., Bangalore N., El-Ashry D., Fuxman Y., Johnson M., Norris B., Oberst M., Ness E., Wojtowicz-Praga S., Bhargava P., Rizvi N., Baidas S., and Michael J. Phase I study of prolonged infusion Bryostatin-1 in patients. Cancer Biol Ther 1 (2002) 409-416
236. Haas N.B., Smith M., Lewis N., Littman L., Yeslow G., Joshi I.D., Murgo A., Bradley J., Gordon R., Wang H., Rogatko A., and Hudes G.R. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res 9 (2003) 109-114
237. Madhusudan S., Protheroe A., Propper D., Han C., Corrie P., Earl H., Hancock B., Vasey P., Turner A., Balkwill F., Hoare S., and Harris A.L. A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. Br J Cancer 89 (2003) 1418-1422
238. Villalona-Calero M.A., Ritch P., Figueroa J.A., Otterson G.A., Belt R., Dow E., George S., Leonardo J., McCachren S.G., Miller G.L., Modiano M., Valdivieso M., Geary R., Oliver J.W., and Holmlund J.A. A phase I/II study of LY900003, an antisense inhibitor of protein kinase Cα, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 10 (2004) 6086-6093
239. Advani R., Lum B.L., Fisher G.A., Halsey J., Geary R.S., Holmlund J.T., Kwoh T.J., Dorr F.A., and Sikic B.I. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs 23 (2005) 467-477
240. Grossman S.A., Alavi J.B., Supko J.G., Carson K.A., Priet R., Dorr F.A., Grundy J.S., and Holmlund J.T. Efficacy and toxicity of the antisense oligonucleotide Aprinocarsen directed aginst protein kinase Cα delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro-Oncology 7 (2005) 32-40
241. Bhonde M.R., Hanski M.L., Margrini R., Moorthy D., Mueller A., Sausville E.A., Kohno K., Wiegland P., Daniel P.T., Zeitz M., and Hanski C. The broad-range cyclin-dependent kinase inhibitor UNC-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the bcl-x protein. Oncogene 24 (2005) 148-156
242. Dees E.C., Baker S.D., O'Reilly S., Rudek M.A., Davidson S.B., Aylesworth C., Elza-Brown K., Carducci M.A., and Donehower R.C. A phase I and pharmacokinetics study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res 11 (2005) 664-671
243. Kortmansky J., Shah M.A., Kaubisch A., Weyerbacher A., Yi S., Tong W., Sowers R., Gonen M., O'Reilly E., Kemeny N., Ilson D.I., Saltz L.B., Maki R.G., Kelsen D.P., and Schwartz G.K. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 23 (2005) 1875-1884
244. Lara Jr. P.N., Mack P.C., Synold T., Frankel P., Longmate J., Gumerlock P.H., Doroshow J.H., and Gandara D.R. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 11 (2005) 4444-4450
245. Herbst RS, Thornton DE, Kies MS, Sinha V, Flanagan S, Cassidy CA, Carducci MA. Phase 1 study of LY317615, a protein kinase Cβ inhibitor. American Society of Clinical Oncology Annual Meeting 2002, Abstract 326.
246. Fine H.A., Kim L., Royce C., Draper D., Haggarty I., Ellinzano H., Albert P., Kinney P., Musib L., and Thornton D. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 23 (2005) 1504
247. Edwards L.A., Thiessen B., Dragowska W.H., Daynard T., Bally M.B., and Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 24 (2005) 3596-3605
248. White D.E., Cardiff R.D., Dedhar S., and Muller W.J. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 20 (2001) 7064-7072
249. Yoganathan N., Yee A., Zhang Z., Leung D., Yan J., Fazli L., Kojic D.L., Costello P.C., Jabali M., Dedhar S., and Sanghera J. Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties. Pharmacol Ther 93 (2002) 233-242
250. Hannigan G., Troussard A.A., and Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5 (2005) 51-63
251. Yau C.Y.F., Wheeler J.J., Sutton K.L., and Hedley D.W. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 65 (2005) 1497-1504
252. Tan C., Cruet-Hennequart S., Troussard A., Fazli L., Costello P., Sutton K., Wheeler J., Gleave M., Sanghera J., and Dedhar S. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5 (2004) 79-90
253. Revets H., De Baetselier P., and Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 5 (2005) 111-124
254. Cortez-Retamozo V., Backmann N., Senter P.D., Wernery U., De Baetselier P., Muyldermans S., and Revets H. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64 (2004) 2853-2857
255. Parsons D.W., Wang T.L., Samuels Y., Bardelli A., Cummins J.M., DeLong L., Silliman N., Ptak J., Szabo S., Willson J.K.V., Markowitz S., Kinzler K.W., Vogelstein B., Lengauer C., and Velculescu V.E. Colorectal cancer: mutations in a signalling pathway. Nature 436 (2005) 792
256. Clark D.E., Errington T.M., Smith J.A., Frieson Jr. H.F., Weber M.J., and Lannigan D.A. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res 65 (2005) 3108-3116